- Home
- BCDA vs PHIO Comparison
BCDA vs PHIO Comparison
Compare BCDA & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- PHIO
- Stock Information
- Founded
- BCDA N/A
- PHIO 2011
- Country
- BCDA United States
- PHIO United States
- Employees
- BCDA N/A
- PHIO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- PHIO Health Care
- Exchange
- BCDA Nasdaq
- PHIO Nasdaq
- Market Cap
- BCDA 11.3M
- PHIO 12.1M
- IPO Year
- BCDA N/A
- PHIO N/A
- Fundamental
- Price
- BCDA $2.06
- PHIO $2.04
- Analyst Decision
- BCDA Strong Buy
- PHIO Strong Buy
- Analyst Count
- BCDA 1
- PHIO 3
- Target Price
- BCDA $25.00
- PHIO $10.67
- AVG Volume (30 Days)
- BCDA 62.9K
- PHIO 139.7K
- Earning Date
- BCDA 08-11-2025
- PHIO 08-14-2025
- Dividend Yield
- BCDA N/A
- PHIO N/A
- EPS Growth
- BCDA N/A
- PHIO N/A
- EPS
- BCDA N/A
- PHIO N/A
- Revenue
- BCDA N/A
- PHIO N/A
- Revenue This Year
- BCDA N/A
- PHIO N/A
- Revenue Next Year
- BCDA N/A
- PHIO N/A
- P/E Ratio
- BCDA N/A
- PHIO N/A
- Revenue Growth
- BCDA N/A
- PHIO N/A
- 52 Week Low
- BCDA $1.63
- PHIO $0.97
- 52 Week High
- BCDA $3.26
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- BCDA 56.99
- PHIO 42.33
- Support Level
- BCDA $1.90
- PHIO $1.96
- Resistance Level
- BCDA $1.99
- PHIO $2.13
- Average True Range (ATR)
- BCDA 0.08
- PHIO 0.10
- MACD
- BCDA 0.03
- PHIO 0.01
- Stochastic Oscillator
- BCDA 90.00
- PHIO 44.83
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.